COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors， steroids, combination therapies, etc.

The global COPD Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.

This report aims to provide a comprehensive presentation of the global market for COPD Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COPD Drugs.

Report Scope

The COPD Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global COPD Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the COPD Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of COPD Drugs Market Report

Report Metric	Details
Report Name	COPD Drugs Market
Segment by Type	Bronchodilators PDE-4 Inhibitors Steroids Combination Therapies Others
Segment by Application	Hospitals Clinics Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Mylan NV
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of COPD Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the COPD Drugs Market report?

Ans: The main players in the COPD Drugs Market are Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Mylan NV

What are the Application segmentation covered in the COPD Drugs Market report?

Ans: The Applications covered in the COPD Drugs Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the COPD Drugs Market report?

Ans: The Types covered in the COPD Drugs Market report are Bronchodilators, PDE-4 Inhibitors, Steroids, Combination Therapies, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global COPD Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Bronchodilators

1.2.3 PDE-4 Inhibitors

1.2.4 Steroids

1.2.5 Combination Therapies

1.2.6 Others

1.3 Market by Application

1.3.1 Global COPD Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global COPD Drugs Market Perspective (2019-2030)

2.2 COPD Drugs Growth Trends by Region

2.2.1 Global COPD Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 COPD Drugs Historic Market Size by Region (2019-2024)

2.2.3 COPD Drugs Forecasted Market Size by Region (2025-2030)

2.3 COPD Drugs Market Dynamics

2.3.1 COPD Drugs Industry Trends

2.3.2 COPD Drugs Market Drivers

2.3.3 COPD Drugs Market Challenges

2.3.4 COPD Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top COPD Drugs Players by Revenue

3.1.1 Global Top COPD Drugs Players by Revenue (2019-2024)

3.1.2 Global COPD Drugs Revenue Market Share by Players (2019-2024)

3.2 Global COPD Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by COPD Drugs Revenue

3.4 Global COPD Drugs Market Concentration Ratio

3.4.1 Global COPD Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by COPD Drugs Revenue in 2023

3.5 COPD Drugs Key Players Head office and Area Served

3.6 Key Players COPD Drugs Product Solution and Service

3.7 Date of Enter into COPD Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 COPD Drugs Breakdown Data by Type

4.1 Global COPD Drugs Historic Market Size by Type (2019-2024)

4.2 Global COPD Drugs Forecasted Market Size by Type (2025-2030)

5 COPD Drugs Breakdown Data by Application

5.1 Global COPD Drugs Historic Market Size by Application (2019-2024)

5.2 Global COPD Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America COPD Drugs Market Size (2019-2030)

6.2 North America COPD Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America COPD Drugs Market Size by Country (2019-2024)

6.4 North America COPD Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe COPD Drugs Market Size (2019-2030)

7.2 Europe COPD Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe COPD Drugs Market Size by Country (2019-2024)

7.4 Europe COPD Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific COPD Drugs Market Size (2019-2030)

8.2 Asia-Pacific COPD Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific COPD Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific COPD Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America COPD Drugs Market Size (2019-2030)

9.2 Latin America COPD Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America COPD Drugs Market Size by Country (2019-2024)

9.4 Latin America COPD Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa COPD Drugs Market Size (2019-2030)

10.2 Middle East & Africa COPD Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa COPD Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa COPD Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer COPD Drugs Introduction

11.1.4 Pfizer Revenue in COPD Drugs Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis COPD Drugs Introduction

11.2.4 Novartis Revenue in COPD Drugs Business (2019-2024)

11.2.5 Novartis Recent Development

11.3 GlaxoSmithKline

11.3.1 GlaxoSmithKline Company Detail

11.3.2 GlaxoSmithKline Business Overview

11.3.3 GlaxoSmithKline COPD Drugs Introduction

11.3.4 GlaxoSmithKline Revenue in COPD Drugs Business (2019-2024)

11.3.5 GlaxoSmithKline Recent Development

11.4 Merck

11.4.1 Merck Company Detail

11.4.2 Merck Business Overview

11.4.3 Merck COPD Drugs Introduction

11.4.4 Merck Revenue in COPD Drugs Business (2019-2024)

11.4.5 Merck Recent Development

11.5 Abbott Laboratories

11.5.1 Abbott Laboratories Company Detail

11.5.2 Abbott Laboratories Business Overview

11.5.3 Abbott Laboratories COPD Drugs Introduction

11.5.4 Abbott Laboratories Revenue in COPD Drugs Business (2019-2024)

11.5.5 Abbott Laboratories Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Detail

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim COPD Drugs Introduction

11.6.4 Boehringer Ingelheim Revenue in COPD Drugs Business (2019-2024)

11.6.5 Boehringer Ingelheim Recent Development

11.7 AstraZeneca

11.7.1 AstraZeneca Company Detail

11.7.2 AstraZeneca Business Overview

11.7.3 AstraZeneca COPD Drugs Introduction

11.7.4 AstraZeneca Revenue in COPD Drugs Business (2019-2024)

11.7.5 AstraZeneca Recent Development

11.8 Roche Holding AG

11.8.1 Roche Holding AG Company Detail

11.8.2 Roche Holding AG Business Overview

11.8.3 Roche Holding AG COPD Drugs Introduction

11.8.4 Roche Holding AG Revenue in COPD Drugs Business (2019-2024)

11.8.5 Roche Holding AG Recent Development

11.9 Teva Pharmaceutical Industries

11.9.1 Teva Pharmaceutical Industries Company Detail

11.9.2 Teva Pharmaceutical Industries Business Overview

11.9.3 Teva Pharmaceutical Industries COPD Drugs Introduction

11.9.4 Teva Pharmaceutical Industries Revenue in COPD Drugs Business (2019-2024)

11.9.5 Teva Pharmaceutical Industries Recent Development

11.10 Vectura Group

11.10.1 Vectura Group Company Detail

11.10.2 Vectura Group Business Overview

11.10.3 Vectura Group COPD Drugs Introduction

11.10.4 Vectura Group Revenue in COPD Drugs Business (2019-2024)

11.10.5 Vectura Group Recent Development

11.11 Mylan NV

11.11.1 Mylan NV Company Detail

11.11.2 Mylan NV Business Overview

11.11.3 Mylan NV COPD Drugs Introduction

11.11.4 Mylan NV Revenue in COPD Drugs Business (2019-2024)

11.11.5 Mylan NV Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Teva Pharmaceutical Industries

Vectura Group

Mylan NV

List of Tables

Table 1. Global COPD Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Bronchodilators

Table 3. Key Players of PDE-4 Inhibitors

Table 4. Key Players of Steroids

Table 5. Key Players of Combination Therapies

Table 6. Key Players of Others

Table 7. Global COPD Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global COPD Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global COPD Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global COPD Drugs Market Share by Region (2019-2024)

Table 11. Global COPD Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global COPD Drugs Market Share by Region (2025-2030)

Table 13. COPD Drugs Market Trends

Table 14. COPD Drugs Market Drivers

Table 15. COPD Drugs Market Challenges

Table 16. COPD Drugs Market Restraints

Table 17. Global COPD Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global COPD Drugs Market Share by Players (2019-2024)

Table 19. Global Top COPD Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COPD Drugs as of 2023)

Table 20. Ranking of Global Top COPD Drugs Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by COPD Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players COPD Drugs Product Solution and Service

Table 24. Date of Enter into COPD Drugs Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global COPD Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global COPD Drugs Revenue Market Share by Type (2019-2024)

Table 28. Global COPD Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global COPD Drugs Revenue Market Share by Type (2025-2030)

Table 30. Global COPD Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global COPD Drugs Revenue Market Share by Application (2019-2024)

Table 32. Global COPD Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global COPD Drugs Revenue Market Share by Application (2025-2030)

Table 34. North America COPD Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America COPD Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America COPD Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe COPD Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe COPD Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe COPD Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific COPD Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific COPD Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific COPD Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America COPD Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America COPD Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America COPD Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa COPD Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa COPD Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa COPD Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 49. Pfizer Company Detail

Table 50. Pfizer Business Overview

Table 51. Pfizer COPD Drugs Product

Table 52. Pfizer Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 53. Pfizer Recent Development

Table 54. Novartis Company Detail

Table 55. Novartis Business Overview

Table 56. Novartis COPD Drugs Product

Table 57. Novartis Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 58. Novartis Recent Development

Table 59. GlaxoSmithKline Company Detail

Table 60. GlaxoSmithKline Business Overview

Table 61. GlaxoSmithKline COPD Drugs Product

Table 62. GlaxoSmithKline Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 63. GlaxoSmithKline Recent Development

Table 64. Merck Company Detail

Table 65. Merck Business Overview

Table 66. Merck COPD Drugs Product

Table 67. Merck Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 68. Merck Recent Development

Table 69. Abbott Laboratories Company Detail

Table 70. Abbott Laboratories Business Overview

Table 71. Abbott Laboratories COPD Drugs Product

Table 72. Abbott Laboratories Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 73. Abbott Laboratories Recent Development

Table 74. Boehringer Ingelheim Company Detail

Table 75. Boehringer Ingelheim Business Overview

Table 76. Boehringer Ingelheim COPD Drugs Product

Table 77. Boehringer Ingelheim Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 78. Boehringer Ingelheim Recent Development

Table 79. AstraZeneca Company Detail

Table 80. AstraZeneca Business Overview

Table 81. AstraZeneca COPD Drugs Product

Table 82. AstraZeneca Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 83. AstraZeneca Recent Development

Table 84. Roche Holding AG Company Detail

Table 85. Roche Holding AG Business Overview

Table 86. Roche Holding AG COPD Drugs Product

Table 87. Roche Holding AG Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 88. Roche Holding AG Recent Development

Table 89. Teva Pharmaceutical Industries Company Detail

Table 90. Teva Pharmaceutical Industries Business Overview

Table 91. Teva Pharmaceutical Industries COPD Drugs Product

Table 92. Teva Pharmaceutical Industries Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 93. Teva Pharmaceutical Industries Recent Development

Table 94. Vectura Group Company Detail

Table 95. Vectura Group Business Overview

Table 96. Vectura Group COPD Drugs Product

Table 97. Vectura Group Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 98. Vectura Group Recent Development

Table 99. Mylan NV Company Detail

Table 100. Mylan NV Business Overview

Table 101. Mylan NV COPD Drugs Product

Table 102. Mylan NV Revenue in COPD Drugs Business (2019-2024) & (US$ Million)

Table 103. Mylan NV Recent Development

Table 104. Research Programs/Design for This Report

Table 105. Key Data Information from Secondary Sources

Table 106. Key Data Information from Primary Sources

List of Figures

Figure 1. Global COPD Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global COPD Drugs Market Share by Type: 2023 VS 2030

Figure 3. Bronchodilators Features

Figure 4. PDE-4 Inhibitors Features

Figure 5. Steroids Features

Figure 6. Combination Therapies Features

Figure 7. Others Features

Figure 8. Global COPD Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global COPD Drugs Market Share by Application: 2023 VS 2030

Figure 10. Hospitals Case Studies

Figure 11. Clinics Case Studies

Figure 12. Others Case Studies

Figure 13. COPD Drugs Report Years Considered

Figure 14. Global COPD Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global COPD Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global COPD Drugs Market Share by Region: 2023 VS 2030

Figure 17. Global COPD Drugs Market Share by Players in 2023

Figure 18. Global Top COPD Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COPD Drugs as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by COPD Drugs Revenue in 2023

Figure 20. North America COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America COPD Drugs Market Share by Country (2019-2030)

Figure 22. United States COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe COPD Drugs Market Share by Country (2019-2030)

Figure 26. Germany COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific COPD Drugs Market Share by Region (2019-2030)

Figure 34. China COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America COPD Drugs Market Share by Country (2019-2030)

Figure 42. Mexico COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa COPD Drugs Market Share by Country (2019-2030)

Figure 46. Turkey COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia COPD Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Pfizer Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 49. Novartis Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 50. GlaxoSmithKline Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 51. Merck Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 52. Abbott Laboratories Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 53. Boehringer Ingelheim Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 54. AstraZeneca Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 55. Roche Holding AG Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 56. Teva Pharmaceutical Industries Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 57. Vectura Group Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 58. Mylan NV Revenue Growth Rate in COPD Drugs Business (2019-2024)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions